DNB Asset Management AS Cuts Stock Position in IQVIA Holdings Inc. $IQV

DNB Asset Management AS trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 81,265 shares of the medical research company’s stock after selling 8,000 shares during the quarter. DNB Asset Management AS’s holdings in IQVIA were worth $15,435,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of IQV. Eubel Brady & Suttman Asset Management Inc. acquired a new stake in IQVIA in the 3rd quarter valued at about $14,278,000. OPTIMAS CAPITAL Ltd purchased a new stake in shares of IQVIA during the third quarter worth approximately $4,008,000. Eagle Rock Investment Company LLC raised its holdings in IQVIA by 33.6% in the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after acquiring an additional 11,657 shares in the last quarter. Amundi lifted its stake in IQVIA by 46.3% in the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after acquiring an additional 405,250 shares during the last quarter. Finally, EDENTREE ASSET MANAGEMENT Ltd acquired a new position in IQVIA during the 3rd quarter worth approximately $7,368,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Up 5.0%

IQV opened at $179.09 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The business’s 50 day moving average is $212.19 and its two-hundred day moving average is $208.00. The firm has a market cap of $30.39 billion, a price-to-earnings ratio of 22.79, a price-to-earnings-growth ratio of 1.72 and a beta of 1.37.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

IQV has been the topic of a number of analyst reports. Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Barclays cut their price target on IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research note on Friday, February 6th. Morgan Stanley set a $240.00 price objective on IQVIA in a research report on Wednesday, February 11th. Mizuho set a $215.00 target price on IQVIA in a research report on Monday, February 23rd. Finally, TD Cowen upped their price target on IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $231.80.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.